Recent investigations have focused on the convergence of GLP|GIP|glucagon receptor stimulant therapies and dopamine neurotransmission. While GCGR agonists are commonly employed for treating type 2 T2DM, their potential effects on reward circuits, specifically influenced by dopamine networks, are attracting considerable interest. This report provide